Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

OBGate

Financiado

Creating an orthogonal gate to the brain

Many impairing illnesses raging from metastatic cancers to neurodegenerative diseases affect the brain. Unfortunately, delivery of therapeutics to the brain is highly challenging due to the blood-brain barrier (BBB). Despite decad... ver más

31/05/2028

INSTITUT QUIMIC DE...

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

INSTITUT QUIMIC DE SARRIA CENTRE D ENSENYAMEN... Educación universitaria asociacion

TRL 4-5 | 50K€

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-02-28

ERC-2022-STG: ERC STARTING GRANTS Scope:Objectives

I+D

Cerrada hace 2 años

0% 100% 100%

1 Participantes

INSTITUT QUIMIC DE SARRIA CE...

1.50M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2017-91909-EXP CONTROL DIFERENCIAL DEL TRANSPORTE DE VEHICULOS TERAPEUTICOS... 54K€ Cerrado

PID2019-108806RB-I00 APROXIMACION SINERGICA AL DESARROLLO DE TERAPIAS PARA TUMORE... 242K€ Cerrado

DeliChoP Drug DELIvery to the brain via CHOroid Plexus targeting 2M€ Cerrado

EIN2019-103356 PORTADOR POLIPEPTIDICO INTRANASAL PARA EL TRATAMIENTO DE PAT... 10K€ Cerrado

Beyond the BBB Nerve Growth Factor Delivery into the Brain – focus on thera... 215K€ Cerrado

CNS2023-144443 Biotecnología 200K€ Cerrado

Duración del proyecto: 63 meses Fecha Inicio: 2023-02-28
Fecha Fin: 2028-05-31

Líder del proyecto

INSTITUT QUIMIC DE SARRIA CENTRE D ENSENYAMEN... Educación universitaria asociacion

TRL 4-5 | 50K€

Presupuesto del proyecto 1M€

Descripción del proyecto Many impairing illnesses raging from metastatic cancers to neurodegenerative diseases affect the brain. Unfortunately, delivery of therapeutics to the brain is highly challenging due to the blood-brain barrier (BBB). Despite decades of research, no safe and efficient strategy to overcome this barrier has reached clinical application. Here we propose a concept that will revolutionize brain transport: creating a new orthogonal receptor to mediate transport across the BBB. Numerous molecules have been developed to achieve brain delivery via receptor-mediated transport. However, delivery is very limited presumably because no receptor combines 3 key features: high transport efficiency, high expression on the BBB, and low expression on peripheral tissues. This results into peripheral tissues acting as a sink and dramatically lowering the therapeutic index of drugs aimed for the brain. The greatest limitation of current efforts is trying to solve both selectivity and efficient transport in a single delivery vehicle. Our unprecedented approach is based on dissecting this problem in two: increasing transport efficiency with the new orthogonal receptor OBGate and addressing selectivity with a highly efficient targeted vehicle to express the receptor only at the BBB. Since this receptor will not bind any endogenous ligand, its properties and intercellular trafficking can be engineered with minimal alteration of brain homeostasis. This will enable to unravel the key determinants of BBB transport and to build an ideal transport system. Selective expression of this receptor in the brain endothelium will be achieved by engineering a gene delivery nanocarrier mimicking the two-stage viral entry into BBB cells. As an example to prove the efficiency of our system we will aim to deliver biotherapeutics for the treatment of brain metastatic breast cancer. Overall, we will open a new gate to the brain that is poised to be paradigm-breaking in the treatment of neurological diseases.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores